Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 21 04:00PM ET
217.93
Dollar change
0.00
Percentage change
0.00
%
IndexS&P 500 P/E46.65 EPS (ttm)4.67 Insider Own0.33% Shs Outstand83.90M Perf Week-2.42%
Market Cap18.28B Forward P/E13.55 EPS next Y16.09 Insider Trans-0.74% Shs Float83.63M Perf Month-3.47%
Income418.00M PEG5.00 EPS next Q3.54 Inst Own98.01% Short Float2.99% Perf Quarter2.93%
Sales12.90B P/S1.42 EPS this Y8.97% Inst Trans-2.78% Short Ratio3.46 Perf Half Y1.07%
Book/sh93.86 P/B2.32 EPS next Y8.86% ROA2.08% Short Interest2.50M Perf Year-1.01%
Cash/sh6.40 P/C34.06 EPS next 5Y9.32% ROE4.27% 52W Range179.58 - 234.09 Perf YTD-4.12%
Dividend Est.2.23 (1.02%) P/FCF20.92 EPS past 5Y-11.15% ROI3.30% 52W High-6.90% Beta1.03
Dividend TTM2.68 (1.23%) Quick Ratio1.02 Sales past 5Y2.46% Gross Margin25.22% 52W Low21.36% ATR (14)4.77
Dividend Ex-DateFeb 26, 2024 Current Ratio1.17 EPS Y/Y TTM-66.36% Oper. Margin8.80% RSI (14)43.57 Volatility2.77% 2.09%
Employees80000 Debt/Eq0.76 Sales Y/Y TTM-13.28% Profit Margin3.24% Recom1.94 Target Price246.07
Option/ShortYes / Yes LT Debt/Eq0.61 EPS Q/Q-328.04% Payout60.38% Rel Volume0.00 Prev Close217.93
Sales Surprise0.51% EPS Surprise1.32% Sales Q/Q-17.44% EarningsFeb 15 BMO Avg Volume723.14K Price217.93
SMA20-2.25% SMA50-2.50% SMA2004.11% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Feb-09-24Initiated Evercore ISI In-line $240
Jan-03-24Initiated Barclays Equal Weight $222
Sep-06-23Initiated HSBC Securities Hold $210
Dec-12-22Downgrade Citigroup Buy → Neutral $275 → $250
Sep-19-22Downgrade Argus Buy → Hold
Aug-22-22Resumed Morgan Stanley Overweight $300
Jan-28-22Downgrade Deutsche Bank Buy → Hold $330 → $294
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Feb-21-24 12:00PM
08:19AM
Feb-19-24 06:28AM
Feb-16-24 09:41AM
07:15AM
12:59AM Loading…
12:59AM
Feb-15-24 03:29PM
12:48PM
09:30AM
08:10AM
07:37AM
07:35AM
07:30AM
06:56AM
Feb-12-24 09:16AM
10:00AM Loading…
Feb-08-24 10:00AM
04:08AM
Feb-07-24 09:05AM
Feb-05-24 08:16AM
Feb-01-24 04:55PM
07:00AM
Jan-31-24 07:00AM
Jan-16-24 06:58AM
Jan-12-24 06:57AM
Jan-11-24 11:21AM
Jan-10-24 08:02AM
Jan-05-24 04:45AM
Jan-02-24 07:00AM
Dec-29-23 09:23AM
Dec-26-23 03:59PM
09:03AM Loading…
Dec-21-23 09:03AM
Dec-17-23 05:05AM
Nov-30-23 07:46PM
Nov-27-23 08:35AM
Nov-24-23 07:21AM
Nov-22-23 05:04AM
Nov-20-23 07:00AM
Nov-16-23 07:00AM
Nov-08-23 07:00AM
Nov-06-23 05:07AM
Oct-31-23 01:17AM
Oct-28-23 02:29PM
Oct-27-23 08:30AM
08:30AM
Oct-26-23 11:13PM
04:19PM
02:51PM
10:36AM
09:30AM
08:48AM
08:15AM
08:08AM
07:06AM
06:58AM
Oct-23-23 06:26AM
Oct-19-23 10:01AM
Oct-16-23 08:30PM
Oct-13-23 08:28AM
Oct-12-23 06:56AM
Oct-11-23 08:30AM
07:30AM
Oct-05-23 10:08AM
Oct-04-23 04:25PM
Sep-29-23 06:57AM
Sep-28-23 09:06AM
Sep-27-23 11:15AM
Sep-19-23 07:20AM
05:00AM
Sep-14-23 06:56AM
Sep-11-23 07:45PM
Sep-04-23 12:06PM
Aug-28-23 10:40AM
Aug-17-23 09:26PM
Aug-15-23 05:38AM
Aug-14-23 03:15PM
Aug-08-23 04:05PM
Aug-07-23 09:57AM
09:57AM
Aug-03-23 02:56PM
08:35AM
07:00AM
Jul-31-23 06:57AM
Jul-28-23 02:15PM
02:48AM
Jul-27-23 03:24PM
02:31PM
02:24PM
01:00PM
11:38AM
08:44AM
08:41AM
07:09AM
06:57AM
02:00AM
Jul-26-23 11:04AM
Jul-24-23 04:27PM
07:22AM
Jul-20-23 10:02AM
Jul-19-23 12:14PM
Jul-17-23 09:13AM
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 13Sale226.4523753,6697,637Feb 15 08:32 AM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 08Sale222.0625957,5147,637Feb 09 12:19 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05Sale220.5719342,5707,637Feb 06 03:47 PM
Wilkinson Peter JSVP, Chief Accounting OfficerNov 16Sale210.711,384291,6272,087Nov 20 12:23 PM
ANDERSON KERRII BDirectorAug 08Sale211.575,0001,057,83215,275Aug 10 08:55 AM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 29Sale240.0021250,8807,605Jul 03 11:52 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19Option Exercise182.514,300784,79317,246May 23 08:06 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19Sale216.914,300932,70712,946May 23 08:06 AM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18Option Exercise130.601,500195,9008,187May 22 03:08 PM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18Sale216.771,500325,1556,687May 22 03:08 PM
Schroeder Mark SEVP, President-Diagnostics LabMar 31Sale225.813,897879,9826,687Apr 03 10:05 AM